Lyra Therapeutics, Inc.
LYRADrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How LYRA's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LYR-210 | Phase 3 | Chronic Sinusitis | - | - |
LYR-220 Design 1 (Part 1 only) | Phase 2 | Chronic Sinusitis | - | - |
Frequently asked questions
What is in Lyra Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Lyra Therapeutics, Inc.'s (LYRA) pipeline across Phase 3, Phase 2. Its lead program is LYR-210 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lyra Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Lyra Therapeutics, Inc. (LYRA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LYRA biotech catalysts?→
Add LYRA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lyra Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.